Special Offers & Promotions



Latest News



View Channel

New Products



View Channel

Video Presentations



View Channel

Separation Science



View Channel

Microscopy & Image Analysis



View Channel

Laboratory Automation & IT Solutions



View Channel


Sartorius Introduces BioPAT

publication date: Mar 3, 2020
author/source: Sartorius Group
ambr® 15 cell culture system with ambr® analysis module showing BioPAT® Spectro port; to which a probe for Raman spectrometer is connected

Sartorius, a leading international partner of the biopharmaceutical industry has introduced BioPAT® Spectro, a Quality by Design (QbD) tool for use with its ambr® automated micro and mini bioreactor systems and with the single-use production bioreactors BIOSTAT STR®.

The new tool offers access to Raman spectroscopy analysis in high throughput process development, supporting faster Raman model building and accelerating scale-up into commercial manufacturing.

Raman spectroscopy is non-invasive and can measure multiple analytes, making it suitable as a Process Analytical Technologies (PAT) method for process control and monitoring of cell cultures. Off-line approaches to obtain and consolidate enough data to produce a robust Raman model can be time?consuming and costly. The new BioPAT® Spectro Tool, can be retrofitted into ambr® 15 cell culture and ambr® 250 high throughput systems, and enables quick and simple sampling for integrated at-line analysis of a large number of analytes by Raman spectroscopy in a Design of Experiments (DoE) approach.

Consisting of a multi-use flow cell integrated into the ambr® analysis module, BioPAT® Spectro in ambr® has been successfully demonstrated by major pharmaceutical companies and is compatible with Raman spectrometers from Kaiser Optical Systems and Tornado Spectral Systems. The online Raman spectroscopy data alongside data from the ambr® process and selected integrated analyzers, is automatically collated by the ambr® software and can be easily transferred to SIMCA® Multivariate Data Analysis (MVDA) software to build robust Raman models.

One benefit of using BioPAT® Spectro with ambr® system is that all integrated sampling, sample analysis, data collection, and consolidation is automated, making walk-away Raman spectroscopy analysis in high throughput process development a reality. Additionally, one ambr® run in 24 mini bioreactors can cover a wide design space, rapidly providing all the data required to build robust Raman models to support QbD, in less than half the time of the conventional benchtop approach.

Developed with scalability in mind, BioPAT® Spectro’s flow cell’s Raman probe interface and optical path design is identical across scales so it enables time-saving, automated in-line Raman spectroscopy with Sartorius’ BIOSTAT STR® single-use bioreactors. The integrated qualified and ready-to-use single-use spectroscopy port in Flexsafe STR® bags for BIOSTAT STR® bioreactors will be launched in the near future.

"Unlocking the potential of Raman spectroscopy as a high throughput analytical technique for monitoring cell culture in mini bioreactors has been a key goal of process development scientists for a number of years,” commented Dr. Svea Cheeseman, Product Manager Process Analytical Technology at Sartorius. “We are showcasing the BioPAT® Spectro at IFPAC and BPI West this year and look forward to discussing with scientists how they can use this new analytical technique with ambr® systems to build and utilize robust Raman models, in a workflow which will support their QbD programs, while minimizing resource costs and biologics’ manufacturing timelines,” adds Dr. Cheeseman.


learn more about BioPAT® Spectro


About Sartorius

The Sartorius Group is a leading international partner of biopharmaceutical research and the industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2019, the company earned sales revenue of some 1.83 billion euros. At the end of 2019, more than 9,000 people were employed at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.


more news from Sartorius

If you have not logged into the website then please enter your details below.


Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin


Request your free copies HERE




Popular this Month

Top 10 most popular articles this month



Today's Picks



Looking for a Supplier?

Search by company or by product


Company Name:






Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


Media Partners


Exhibitions & Events